NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Dyskinesias, Neurologic Manifestations, Nutritional and Metabolic Diseases, Primary Immunodeficiency Diseases, Spinocerebellar Ataxias, atactic disorder, non-human animal, ataxia telangiectasia, brain disorder, cardiovascular disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, hereditary disease, immune system disorder, inborn error of immunity, metabolic disease, nervous system disorder, neurocutaneous syndrome, telangiectasis, vascular disorder	Active, not recruiting	Phase 2	2022-08-17		NCT04870866

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Haukeland University Hospital	163
Oslo University Hospital	327
South-Eastern Norway Regional Health Authority	22
St. Olavs Hospital	167
Sykehuset Innlandet HF	35
The Bergesen Foundation	1
University Hospital of North Norway	93
University Hospital, Akershus	87
University of Bergen	70

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hilde Loge Nilsen	Lørenskog	Norway	1
Oslo University Hospital	Oslo	Norway	111